Clinical trial

Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

NCT06481813

Study summary

ClinicalTrials.gov

Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients

Design: INTERVENTIONAL · Status: RECRUITING · Phase: NA

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

OTHER · Unmapped registry intervention Blood Sampling (2*8mL Tubes) Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention PBMC Sampling (1*8mL Tubes) Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention Paxgene Sampling Find medicine records · Find other trials using this name

PROCEDURE · Unmapped registry intervention Extended biopsies of tumor lesions Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-12-10

PhaseNA

Conditions

Lung Cancerverified · MONDO: lung cancer

Carcinoma, Non-Small-Cell Lungcandidate · MONDO: non-small cell lung carcinoma

Small Cell Lung Carcinomaverified · MONDO: small cell lung carcinoma

Metastatic Lung Cancerunresolved

Interventions

Blood Sampling (2*8mL Tubes)OTHER

PBMC Sampling (1*8mL Tubes)OTHER

Paxgene SamplingOTHER

Extended biopsies of tumor lesionsPROCEDURE

Sponsors & collaborators

Nantes University Hospitallead sponsor

Mapped research locations

NantesFrance1 RennesFrance1 AngersFrance1 ToursFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06481813 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.